Released : September 24, 2018 07:00 RNS Number : 6299B MaxCyte, Inc. 24 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2018 Gaithersburg, Maryland - 24 September 2018 - MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and
Released : September 10, 2018 07:00 RNS Number : 2308A MaxCyte, Inc. 10 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 10 September 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the
Released : July 16, 2018 07:00 RNS Number : 6675U MaxCyte, Inc. 16 July 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Gaithersburg, Maryland - 16 July 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company , provides an update on
Gaithersburg, Maryland – May 29, 2018 MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA Cell Therapy, will present at the 2018 BIO International Convention (Boston Convention Center) on June 6, 2018, at 2:45 p.m. ET. Ms. Bowes will present and discuss MaxCyte’s
Released : April 30, 2018 07:00 RNS Number : 4680M MaxCyte, Inc. 30 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of AGM and 2017 Annual Report and Accounts Gaithersburg, Maryland - 30 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life
Released : April 04, 2018 07:00 RNS Number : 7161J MaxCyte, Inc. 04 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2017 Gaithersburg, Maryland - 04 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines
Gaithersburg, Maryland – 12 March 2018: MaxCyte announced today that Debra K. Bowes, Executive Vice President, Business and Strategic Development , will present at two key life sciences conferences this month: the 12 th Annual International Partnering Conference: BIO Europe Spring on March 14
Released : February 15, 2018 07:00 RNS Number : 9370E MaxCyte, Inc. 15 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA , 15 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that it
Released : January 23, 2018 13:32 RNS Number : 6888C MaxCyte, Inc. 23 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA - 23 January 2018: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 18,293 new shares of common
Released : January 22, 2018 07:00 RNS Number : 4641C MaxCyte, Inc. 22 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Gaithersburg, Maryland - 22 January 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
